Search and analyze individual stocks with comprehensive metrics

Raymed Labs Ltd

RAYLAPharmaceuticals
3.83+0.00 (+0.00%)
As on 02 Jan 2026, 04:03 pmMarket Closed

Fundamental Score

...

Raymed Labs Ltd Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Return on Equity

N/A

Return on Capital Employed

N/A

Operating Profit Margin (5Y)

N/A
Poor

Dividend Yield

0.00%

Valuation Metrics

Price to Earnings

N/A

Market Capitalization

1.64 (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

50.00%

YoY Quarterly Sales Growth

N/A

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Debt to Equity

N/A
Poor

Interest Coverage

-1.55x
Poor

Free Cash Flow (5Y)

-2.25 (Cr)

Ownership Structure

Average

Promoter Holding

32.27%
Poor

FII Holding

0.00%
Poor

DII Holding

0.96%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
32.27%
Promoter Holding
1.64 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of RAYLA across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Robust Profit Growth (50.00%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

5 factors identified

Weak Interest Coverage (-1.55x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.

Negative Free Cash Flow (₹-2.25 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

Limited Institutional Interest (FII+DII: 0.96%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Raymed Labs Ltd

About RAYLA

Company Details

Symbol:RAYLA
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:N/A

RAYLA Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)N/A%
Return on Capital EmployedN/A%
Operating Profit Margin (5Y)N/A%
Debt to Equity RatioN/A
Interest Coverage Ratio-1.55

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth50.00%
YoY Quarterly Sales GrowthN/A%

Frequently Asked Questions

What is the current price of Raymed Labs Ltd (RAYLA)?

As of 02 Jan 2026, 04:03 pm IST, Raymed Labs Ltd (RAYLA) is currently trading at ₹3.83. The stock has a market capitalization of ₹1.64 (Cr).

Is RAYLA share price Overvalued or Undervalued?

RAYLA is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.

What factors affect the Raymed Labs Ltd share price?

Key factors influencing RAYLA's price include its quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Raymed Labs Ltd a good stock for long-term investment?

Raymed Labs Ltd shows a 5-year Profit Growth of N/A% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing.

How does Raymed Labs Ltd compare with its industry peers?

Raymed Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare RAYLA's P/E of 0.00x and ROE of N/A% against the industry averages to determine its competitive standing.

What is the P/E ratio of RAYLA and what does it mean?

RAYLA has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.

How is RAYLA performing according to Bull Run's analysis?

RAYLA has a Bull Run fundamental score of 8/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does RAYLA belong to?

RAYLA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Raymed Labs Ltd.

What is Return on Equity (ROE) and why is it important for RAYLA?

RAYLA has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Raymed Labs Ltd generates profits from shareholders' equity.

How is RAYLA's debt-to-equity ratio and what does it indicate?

RAYLA has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is RAYLA's dividend yield and is it a good dividend stock?

RAYLA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has RAYLA grown over the past 5 years?

RAYLA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in RAYLA and why does it matter?

Promoters hold 32.27% of RAYLA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is RAYLA's market capitalization category?

RAYLA has a market capitalization of ₹2 crores, placing it in the Small-cap category.

How volatile is RAYLA stock?

RAYLA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for RAYLA?

RAYLA has a 52-week high of ₹N/A and low of ₹N/A.

What is RAYLA's operating profit margin trend?

RAYLA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.

How is RAYLA's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of N/A% and YoY Profit Growth of 50.00%.

What is the institutional holding pattern in RAYLA?

RAYLA has FII holding of 0.00% and DII holding of 0.96%. Significant institutional holding often suggests professional confidence in the stock.